Literature DB >> 34082512

Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

Majid Assadi1, Seyed Javad Rekabpour2, Abdullatif Amini3, Habibollah Dadgar4, Reza Nemati5, Ali Gholamrezanezhad6, Iraj Nabipour7, Esmail Jafari1, Hojjat Ahmadzadehfar8.   

Abstract

We present a partial response of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime.

Entities:  

Keywords:  18F-FDG-PET/CT; 68Ga-DOTATATE PET/MRI; PRRT; neuroendocrine tumor

Year:  2021        PMID： 34082512      PMCID： PMC8185482          DOI： 10.4274/mirt.galenos.2020.69783

Source DB:  PubMed          Journal:  Mol Imaging Radionucl Ther        ISSN： 2146-1414


  5 in total

1.  Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

Authors:  Katharina Seystahl; Veit Stoecklein; Ulrich Schüller; Elisabeth Rushing; Guillaume Nicolas; Niklaus Schäfer; Harun Ilhan; Athina Pangalu; Michael Weller; Jörg-Christian Tonn; Michael Sommerauer; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

2.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

Authors:  Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn
Journal:  Neuro Oncol       Date:  2016-02-09       Impact factor: 12.300

3.  Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

Authors:  Esben Andreas Carlsen; Nicola Fazio; Dan Granberg; Simona Grozinsky-Glasberg; Hojjat Ahmadzadehfar; Chiara Maria Grana; Wouter T Zandee; Jaroslaw Cwikla; Martin A Walter; Peter Sandor Oturai; Anja Rinke; Andrew Weaver; Andrea Frilling; Sara Gritti; Anne Kirstine Arveschoug; Amichay Meirovitz; Ulrich Knigge; Halfdan Sorbye
Journal:  Endocr Relat Cancer       Date:  2019-02-01       Impact factor: 5.678

4.  Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT.

Authors:  William Makis; Karey McCann; Alexander J B McEwan
Journal:  Clin Nucl Med       Date:  2015-03       Impact factor: 7.794

5.  Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.

Authors:  Mirco Bartolomei; Lisa Bodei; Concetta De Cicco; Chiara Maria Grana; Marta Cremonesi; Edoardo Botteri; Silvia Melania Baio; Demetrio Aricò; Maddalena Sansovini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-25       Impact factor: 9.236
  5 in total
  1 in total

Review 1.  The Role of [68Ga]Ga-DOTA-SSTR PET Radiotracers in Brain Tumors: A Systematic Review of the Literature and Ongoing Clinical Trials.

Authors:  Paolo Palmisciano; Gina Watanabe; Andie Conching; Christian Ogasawara; Gianluca Ferini; Othman Bin-Alamer; Ali S Haider; Maria Gabriella Sabini; Giacomo Cuttone; Sebastiano Cosentino; Massimo Ippolito; Giuseppe E Umana
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.